



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1219P1C1

Serial No.

10/715,795

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard, A. et al.

Filing Date

17 Nov 2003

Group

1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
OC	* 1	4,378,347	29.03.83	Franco, W.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
OC	* 2	HEI 12-511867	11-2000	JAPAN			
OC	* 3	WO 93/18186	16.09.93	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 4	Abbass et al., "Altered expression of fibroblast growth factor receptors in human pituitary adenomas" <u>Journal of Clinical Endocrinology & Metabolism</u> 82(4):1160-1166 (Apr 1997)
	* 5	Alitalo and Schwab, "Oncogene amplification in tumor cells" <u>Advances in Cancer Research</u> 47:235-281 (1986)
	* 6	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
	* 7	Arman et al., "Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development" <u>Proc. Natl. Acad. Sci. USA</u> 95(9):5082-5087 (Apr 28, 1998)
	* 8	Armstrong et al., "Expression of fibroblast growth factor receptors in human leukemia cells" <u>Cancer Research</u> 52(7):2004-2007 (Apr 1, 1992)
OC	* 9	Aviezer et al., "Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis" <u>Cell</u> 79(6):1005-1013 (Dec 16, 1994)
	* 10	Baird and Bohlen, "Fibroblast Growth Factors" <u>Handbook of Exp. Pharmacol.</u> , Chapter 7, 95(1):369-418 (1990)
	* 11	Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic Implications" <u>Oncology</u> (Supplement No. 2) 11(3):43-48 (March 1997)
	* 12	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
	* 13	Bashkin et al., "Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules" <u>Biochemistry</u> 28(4):1737-1743 (Feb 21, 1989)
	* 14	Bishop, J., "Molecular themes in oncogenesis" <u>Cell</u> 64(2):235-248 (Jan 25, 1991)
	* 15	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" <u>Science</u> 247:1306-1310 (1990)
	* 16	Ciruna et al., "Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak" <u>Development</u> 124(14):2829-2841 (Jul 1997)
	* 17	Colvin et al., "Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3" <u>Nature Genetics</u> 12(4):390-397 (Apr 1996)
	* 18	Dell and Williams, "A novel form of fibroblast growth factor receptor 2. Alternative splicing of the third immunoglobulin-like domain confers ligand binding specificity" <u>Journal of Biological Chemistry</u> 267(29):21225-21229 (Oct 15, 1992)

Examiner

Date Considered

7/15/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.